PMID: 6113732Jan 1, 1981Paper

Neurotransmitter receptors in brain in schizophrenia

Acta Psychiatrica Scandinavica. Supplementum
F OwenM Poulter

Abstract

The binding of the dopamine agonist ADTN and of ligands for the serotonin, muscarinic cholinergic, GABA, and benzodiazepine receptors was studied in 18 schizophrenic and 19 control brains. By contrast with the previously reported increase in binding of the dopamine antagonist spiperone, ADTN binding was not increased, and there was no consistent change in binding of ligands for receptors of substances other than dopamine. The findings suggest that the increase in dopamine receptors (assessed by spiperone binding) in schizophrenia is related to the disease process rather than to previous neuroleptic medication, and may be limited to the type of dopamine receptors that bind butyrophenones.

References

Jun 10, 1976·The New England Journal of Medicine·S J EnnaS H Snyder
Jun 15, 1979·European Journal of Pharmacology·I Creese, S H Snyder
Oct 15, 1977·Life Sciences·T D ReisineH I Yamamura
Aug 1, 1977·Life Sciences·T D ReisineH I Yamamura
Apr 15, 1979·European Journal of Pharmacology·P SeemanJ A Poat
Aug 11, 1975·Archives of General Psychiatry·R M PostF K Goodwin
May 1, 1974·Proceedings of the National Academy of Sciences of the United States of America·H I Yamamura, S H Snyder
Jul 1, 1974·Archives of General Psychiatry·M B Bowers
Jan 1, 1972·Archives of General Psychiatry·J P FeighnerR Munoz

❮ Previous
Next ❯

Citations

Jan 1, 1991·Journal of Neural Transmission. General Section·R C Arora, H Y Meltzer
Nov 15, 1982·Experientia·T J Crow
Jul 1, 1995·Biological Psychiatry·R J WyattM F Casanova
Jun 6, 1991·European Journal of Pharmacology·T HashimotoK Kuriyama
Jan 1, 1995·Life Sciences·C J SchmidtM G Palfreyman
Jan 1, 1983·Neuroscience and Biobehavioral Reviews·J N Joyce
May 1, 1993·Psychiatry Research·R C Arora, H Y Meltzer
May 1, 1991·Psychiatry Research·C N KarsonR D Skinner
Dec 4, 1998·Biological Psychiatry·J A LiebermanJ E Kraus
Sep 12, 2000·Psychiatry Research·P GovitrapongA Srikiatkhachorn
Jul 27, 2001·Journal of Chemical Neuroanatomy·T M Hyde, J M Crook
Nov 30, 2007·Progress in Neuro-psychopharmacology & Biological Psychiatry·Mark C McLeodBrian Dean
Oct 30, 2008·Journal of Neurochemistry·Elizabeth Scarr, Brian Dean
Jul 12, 2005·Progress in Neuro-psychopharmacology & Biological Psychiatry·Teresa M du BoisXu-Feng Huang
Aug 24, 2011·Nordic Journal of Psychiatry·Maurizio Coppola, Raffaella Mondola
Nov 19, 2011·The International Journal of Neuropsychopharmacology·Inge KlinkenbergAnke Sambeth
Oct 10, 2007·Harvard Review of Psychiatry·W Gordon Frankle
Dec 25, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Katerina ZavitsanouHuang Xu-Feng

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here